Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Noninvasive method lifts curtain on cerebrospinal-fluid dance in human brain
Cerebrospinal fluid shows brain-region-specific dynamics, a new high-resolution MRI approach reveals.
Noninvasive method lifts curtain on cerebrospinal-fluid dance in human brain
Cerebrospinal fluid shows brain-region-specific dynamics, a new high-resolution MRI approach reveals.
Aging as adaptation: Learning the brain’s recipe for resilience
Some age-related changes in the brain and in behavior are not solely the result of cognitive decline but rather part of a larger adaptive process.
Aging as adaptation: Learning the brain’s recipe for resilience
Some age-related changes in the brain and in behavior are not solely the result of cognitive decline but rather part of a larger adaptive process.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.
Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory
A new review of 15 years of studies on the connection between the microbiome and autism reveals widespread statistical and conceptual errors.